NeuroThera Labs Announces Upsize to Private Placement

NeuroThera Labs Inc. (the “ Company ” or “ NeuroThera ”) (TSXV: NTLX) a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that, further to its press release dated June 30, 2026, it has increased the size of its previously announced non-brokered private placement (the " Offering ") and extended the expiry term of the Unit Warrants (as defined below). The Company now intends to issue up to 45,000,000 units (each, an " Offered Unit ") at a price of C$0.12 per Offered Unit for gross proceeds of up to approximately C$5,400,000 under the Offering. Each Offered Unit will be comprised of one (1) common share in the capital of the Company (each, a " Unit Share ") and one (1) transferable common share purchase warrant (each, a " Unit Warrant ") entitling the holder thereof to acquire one common share in the capital of the Company (each, a " Unit Warrant Share ") at a USD exercise price equivalent to C$0.16 per Unit Warrant Share (to be calculated on the date of closing of the Offering) for a period of 36 months from the date of issuance thereof, an increase to the previously announced 24 month expiry period for the Unit Warrants. The Unit Warrants will also have an acceleration provision whereby upon the securities of NeuroThera being approved for trading on the Nasdaq Stock Market, NeuroThera will accelerate the expiry date of 50% of the unexercised Unit Warrants. The Company intends to use the net proceeds of the Offering for general working capital purposes, including the evaluation of prospective transactions, settlement of liabilities, including repayment of outstanding indebtedness owed to SciSparc Ltd. and other corporate and administrative expenses.